Clin2
NCT04277858Possibly a fitRecruiting

Pre-surgery chemo plus robotic surgery for p16-positive throat cancer

Oropharynx CancerTonsil CancerThroat CancerBase of the Tongue Carcinoma

Treatments studied

Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.

This trial tests whether giving chemotherapy before robotic surgery works well for certain p16-positive oropharyngeal (throat) cancers. It aims to shrink or control the cancer and allow the surgeon to remove the tumor with clean margins while avoiding cancer spread beyond the neck.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You have squamous cell cancer in the oropharynx (throat) that is p16 positive
  • Your cancer is stage III or stage IVA (and not too advanced for surgery as defined by the trial)
  • You have not had cancer treatment yet for this cancer (treatment naive)
  • Cancer is not spread to distant organs (no distant metastasis)
  • A surgeon believes the tumor can be removed through the mouth using a transoral robotic approach with clean margins
  • Your blood counts and kidney function are strong enough for chemo (ANC over 2,000, platelets over 100,000, kidney clearance over 50)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05388773Recruiting· Phase 2
Surgery then lower-dose radiation for p16+ throat cancer

This Phase 2 study tests whether removing the tumor through the mouth, followed by a reduced course of radiation, can control HPV-related (p16+) oropharynx throat cancer. It may help reduce treatment intensity after surgery, while still aiming to keep the cancer from coming back.

Pittsburgh, Pennsylvania
NCT05800574Recruiting· Phase 2
Targeted neck radiation for p16-positive favorable throat cancer

This Phase 2 study tests whether a more precisely targeted radiation plan to the neck can work for people with p16-positive oropharynx cancer that is considered “favorable risk.” Doctors use special imaging to map where lymph nodes are likely involved, aiming to treat the right areas while avoiding unnecessary treatment.

Philadelphia, Pennsylvania
NCT07195734Recruiting· Phase 2
Adding chemo or immunotherapy before surgery for advanced head and neck cancer

This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.

Tucson, Arizona
NCT05419089Recruiting· Phase 2
Testing robotic surgery for HPV-related throat cancer patients

This Phase 2 trial studies a robotic surgery approach for certain HPV-related throat cancers, using HPV blood tests before and after surgery to guide care. If your cancer is HPV-related and your HPV blood test results match the trial targets, you may be able to join and help improve treatment for future patients.

Paramus, New Jersey
NCT04104945Recruiting
Trial to reduce radiation fields in p16+ oropharyngeal cancer

This study tests whether shrinking the “planned radiation area” (elective treatment volumes) can still treat p16-positive oropharyngeal cancer effectively. It may help reduce unnecessary radiation to nearby healthy tissues while keeping the cancer treatment curative.

Calgary, Alberta
NCT05144100Not yet recruiting· Phase 2/Phase 3
Compare surgery vs chemoradiation for HPV-negative throat cancer

This trial compares two standard treatment approaches for oropharyngeal (throat) squamous cell cancer: surgery plus recovery, versus chemotherapy combined with radiation. It is testing which plan works better for patients whose tumors are HPV-negative (p16 negative).

Mumbai, Maharashtra

Hear when a new Oropharynx Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.